Bayer (FRA: BAYN) announced today that it will acquire gene therapy startup AskBio for an upfront payment of $2 billion. The German life sciences giant could shell out an additional $2 billion if the startup meets specific criteria. Rather than folding AskBio’s operations into its own, Bayer stressed in a statement that the startup would operate independently…